- Home
- About
- Products
- E1 Activating
- E2 Conjugating
- E3 Ligase
- Deconjugating
- Proteasome
- Ubiquitin
- All
- Ubiquitin and Ubiquitin Derivatives
- Ubiquitin Chains
- DUB-Resistant, Non-Hydrolyzable Chains
- NH Isopeptide-linked chains
- DCA Linked Chains
- K6-linked Chains (DCA)
- Agarose Bound K6-linked Chains (DCA)
- K11-linked Chains (DCA)
- Agarose Bound K11-linked Chains (DCA)
- K29-linked Chains (DCA)
- Agarose Bound K29-linked Chains (DCA)
- K33-linked Chains (DCA)
- Agarose Bound K33-linked Chains (DCA)
- K48-linked Chains (DCA)
- Agarose Bound K48-linked Chains (DCA)
- K63-linked Chains (DCA)
- Agarose Bound K63-linked Chains (DCA)
- K76-linked Chains (DCA)
- Agarose Bound K76-linked Chains (DCA)
- Ubiquitin Mutants
- Labeled Ubiquitin Proteins
- Antibodies, ELISAs and Kits
- SUMO
- NEDD8
- ISG15
- UFM1
- URM1
- Autophagy
- FAT10
- Inhibitors
- Antibodies
- Kits
- Buffers, Solutions, Standards
- Substrate Proteins
- Affinity Matrices / Proteins
- Fractions
- FUBI
- References
- Orders
- Contact
E3 Ligase - Enzymes
Ubiquitin modification of substrate proteins is achieved by the activity of E1 activating, E2 conjugating and E3 ligase enzymes. Substrate proteins can be modified with one (mono-ubiquitination) or many (poly-ubiquitination) molecules of ubiquitin, and each type of modification has distinct regulatory fates. E3 ligages number in the thousands and have the highest level of specificity for the target protein to be modified by ubiquitin or ubiquitin-like modifiers (UBL).
| E3-100 |
His6-MurF1/TRIM63 |
human recombinant |
25 µg |
275 | Buy / Info |
| E3-150 |
His6-Parkin |
human recombinant |
50 µg |
330 | Buy / Info |
| E3-210 |
RNF4 |
Human Recombinant |
50 µg |
$250 | Buy / Info |
| E3-220 |
CHIP/Stub1 |
Human Recombinant |
50μg |
$250 | Buy / Info |
| E3-230 |
E6AP/UBE3A |
Human Recombinant |
50 μg |
$250 | Buy / Info |







